Zhitong Finance App News, Hengrui Pharmaceutical (01276.HK) announced that recently, the company received a notice from the State Drug Administration to approve the marketing of the company's self-developed class 1 therapeutic biological product called sultiinsulin injection. This product is the first self-developed long-term insulin analogue in China.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.